Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003519priorityCriticalpatent/ECSP003519A/en
Publication of ECSP003519ApublicationCriticalpatent/ECSP003519A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La invención se refiere a compuestos de la fórmula general (gráfico), en donde, R1 significa hidrógeno o hidroxilo; R2 significa hidrógeno o metilo; y X significa -O- ó -CH2-; y a sus sales de adición ácida famacéuticamente aceptables. Se han demostrado que estos compuestos tienen una buena afinidad para el receptor del NMDA y son por lo tanto de utilidad en el tratamiento de enfermedades, en donde las indicaciones terapéuticas incluyen formas agudas de neurodegeneración causadas p.Ej., por una apoplejía o un trauma cerebral; formas crónicas de neurodegeneración tales como la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington o ALS (esclerosis lateral amiotrófica); neurodegeneración asociada con infecciones bacterianas o víricas y enfermedades tales como la esquizofrenia, ansiedad, depresión y dolor crónico/agudo.The invention relates to compounds of the general formula (graph), wherein, R1 means hydrogen or hydroxyl; R2 means hydrogen or methyl; and X means -O- or -CH2-; and to its pharmaceutically acceptable acid addition salts. These compounds have been shown to have a good affinity for the NMDA receptor and are therefore useful in the treatment of diseases, where the therapeutic indications include acute forms of neurodegeneration caused e.g. by stroke or trauma. cerebral; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections and diseases such as schizophrenia, anxiety, depression and chronic / acute pain.
2-AMINA-PYRIMIDINE-4- (2-METHYL-1- (TETRAHIDRO-2H-PIRAN-4-IL) -1-IMIDAZOL-5-Y1) SUBSTITUTED AND ITS DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PROCESSES FOR PREPARATION AND APPLICATIONS
SUBSTITUTED DERIVATIVES OF 3- (4-METOXI-PHENYL) -3H-ISOINDOL-1-ILLUMIN TRIFLUOROACETATE, ITS SALTS OR SOLVATOS PHARMACEUTICALLY ACCEPTABLE, PHARMACEUTICAL FORMULATIONS AND APPLICATIONS.
SUBSTITUTED DERIVATIVES OF 2-AMINO-5,6-DIHIDRO PIRIMIDIN-4 (3H) -ONAS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING AND APPLICATIONS.
SUBSTITUTED DERIVATIVES OF 7-CHLORINE-3H-IMIDAZOL- (4,5-B) PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THE PREPARATION OF THE SAME AND APPLICATIONS